ITGAM and neoplasm: Ibrutinib-treatment resulted in a significant reduction in tumor growth (Figure 5A), as well as in the number of CD11b+Gr1+ MDSCs infiltrated in the tumors and spleens of mice treated with ibrutinib (Figure 5B).